Tagged with Turkey,

pharma Consumer healthcare products manufacturer Winalite is working to penetrate the Turkish market, but with regulations complicating bringing their portfolio from China, general manager Arafat Yadigar is looking to develop a Turkey specific portfolio in collaboration with the Turkish health products and pharmaceutical manufacturing sectors.  Your promotion to General Manager is…

pharma Ozgur Tomruk, J&J’s Managing Director for Global Surgery talks about Turkey’s importance for the company, the priorities they have set, J&J’s commitment to quality and his ambition for the company’s future in Turkey. As an introduction for our readers, Ozgur, can you please give an overview of where J&J Turkey…

pharma Nil Tunaşar, managing partner of Transorient, discusses significance of tracking performance metrics among 3PL providers, the organization’s technology overhaul, and also highlights the type of logistics solutions encompassed under Transorient’s Life Sciences and Biopharma line of business. As an introduction for our readers, Nil, please provide some insight into Transorient’s…

pharma Matthias Diewald (MD) and Asli Volkan (AV) elaborate on HELM Kimya’s longstanding presence within Turkey and the type of market opportunities available for co-development and contract manufacturing. They also explain the significance of establishing strong partnerships with local industry leaders and how this can effectively drive future success for the company’s…

pharma The general manager of Ali Raif, Muzaffer Bal illustrates the various success factors that allowed the company to secure market leading positions within Turkey and across Europe, while also highlighting how the company has adapted its portfolio to shifting market dynamics. Muzaffer, as an introduction for our readers, please provide…

pharma Haluk Ataoglu, academic turned founder of Matriks Biotek®, talks about his aspirations for his company and the Turkish R&D landscape as well as how to penetrate the global pharmaceutical market as a Turkish brand. As an introduction Haluk, can you tell us what your initial aspirations were in starting Matriks…

pharma Prof. Dr. Murat Özgören, the architect behind the ambitious BioIzmir project, talks about its potential and how it intends to educate new talent to address critical future needs of the pharmaceutical industry. To begin, Dr. Özgören, could you give us an overview of the intent behind the BioIzmir project? The…

Turkey BMS Turkey’s new general manager discusses Opdivo (nivolumab) their revolutionary new product for squamous non-small cell lung cancer, their registry of 1200 patients in Turkey with melanoma, potential developments in pharmaceutical pricing through alternative reimbursement models, and BMS’ role in helping to shape health policy around oncology given their revolutionary immuno-oncology…

Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…

Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…

Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…

manufacturing The managing director of Ejder Kimya, Pervin Ejder explains how the landscape for API and raw materials suppliers has evolved in Turkey, and how the company has pivoted into more value added and total packaged solutions to accommodate changing market dynamics. As an introduction for our readers, Pervin, can you…